Información de la revista
Vol. 22. Núm. 6.
Páginas 369-370 (junio 2004)
Vol. 22. Núm. 6.
Páginas 369-370 (junio 2004)
Acceso a texto completo
Utilidad del linezolid en la fibrosis quística
Visitas
6418
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Thomas, K. Gyi, H. Gaya, M. Hodson.
Methicillin- resistant Staphylococcus aureus: impact at a national cystic fibrosis centre.
J Hosp Infect, 40 (1998), pp. 203-209
[2.]
J.J. Picazo, C. Betriu.
Perfil microbiológico de linnezolid.
Enferm Infecc Microbiol Clin, 1 (2002), pp. 8-14
[3.]
C. Pigrau.
Oxalidinonas y glucopéptidos.
Enferm Infecc Microbiol Clin, 21 (2003), pp. 157-165
[4.]
R.C. Moellering.
Linezolid: the first oxazolidinone antimicrobial.
Ann Intern Med, 138 (2003), pp. 135-142
[5.]
E. Bouza, P. Muñoz.
Linezolid: pharmacokinetic characteristics and clinical studies.
Clin Microbiol Infect, 4 (2001), pp. 75-82
[6.]
R. Cantón, R. Girón, L. Martínez-Martínez, A. Oliver, A. Sole, S. Valdezate, et al.
Patógenos multirresistentes en la fibrosis quística.
Arch Bronconeumol, 38 (2002), pp. 376-385
[7.]
D.J. Diekema, M.A. Pfaller, F.J. Schmitz, J. Smayevsky, J. Bell, R.N. Jones, et al.
SENTRY Partcipants Group. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Clin Infect Dis, 15 (2001), pp. S114-S132
[8.]
D. Saralaya, D. Peckham, B. Hulme, C. Tobin, M. Denton, S. Conway, et al.
Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.
J Antimicrob Chemother, 53 (2004), pp. 325-328
[9.]
R. Wunderink, J. Rello, S. Cammarat, C. Cross-Dabrera, M. Kollef.
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Chest, 124 (2003), pp. 1789-1797
[10.]
P. Smith, M. Birmingaham, G. Noskin, A. Meagher, A. Forrest, C. Rayner, et al.
Safety, efficacy and paharcokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients wirth neutropenia.
Annals of Oncology, 14 (2003), pp. 795-801
[11.]
A.F. Shorr, G.M. Susla, M.H. Kollef.
Linezolid for treatment of ventilator-associated pneumonia: cost-effective alternative to vancomycin.
Crit Care Med, 32 (2004), pp. 137-143
[12.]
S. Tsiodras, H.S. Gold, G. Sakoulas, G.M. Eliopoulos, C. Wennersten, L. Venkataraman, et al.
Linezolid resistance in a clinical isolate of Staphylococcus aureus.
Lancet, 358 (2001), pp. 207-208
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados